-
ProductsOur company can produce anti-tumor, anti-fungal, antibiotics, nutrition, anesthesia, cardiovascular and cerebrovascular products such as 6 categories of series of products, the company's existing domestic products 73 product specifications and foreign products 22 product specifications.
-
NewsFrom 2019 to now, the company has attracted 38 kinds of generic drugs developed by 12 scientific research institutes such as Beijing Tongrentang Pharmaceutical Technology Development Co., Ltd. and Shanghai Rongdi Biotechnology Co., Ltd. to land in our company. After all of them are put into production, the annual output value can be increased by 1 billion and the profit can be about 0.2 billion.
Shanxi Nuocheng Pharmaceutical Co., Ltd. Renovation and Expansion of 2 × 63 Tons of Amino Acid Derivative Series and 2 × 4 Tons of Cimetidine Raw Material Drug Production Line Project (Phased) Completion Environmental Protection Acceptance Monitoring Report Publicity
Date:
2023-05-24
According to the "Decision of the State Council on Amending the" Regulations on the Administration of Environmental Protection for the Completion of Construction Projects "(State Council Order No. 682), and the Ministry of Environmental Protection" On Issuing<建设项目竣工环境保护验收暂行办法>(National Environmental Regulations EIA [2017] No. 4), the "Shanxi Nuocheng Pharmaceutical Co., Ltd. reconstruction and expansion of the annual output of 2 x 63 tons of amino acid derivatives series, annual output of 2 x 4 tons of cimetidine bulk drug product production line project (phased) completion of the environmental protection acceptance monitoring report" for the full publication as follows:</建设项目竣工环境保护验收暂行办法>
According to the Decision of the State Council on Amending the Regulations on the Administration of Environmental Protection for the Completion of Construction Projects (Order No. 682 of the State Council), and the Announcement of the Ministry of Environmental Protection on Issuing the Interim Measures for the Acceptance of Environmental Protection for the Completion of Construction Projects (National Environmental Planning and Environmental Assessment [2017] No. 4), now the "Shanxi Nuocheng Pharmaceutical Co., Ltd. reconstruction and expansion of the annual output of 2 × 63 tons of amino acid derivatives series, annual output of 2 × 4 tons of cimetidine bulk drug product production line project (phased) completion of the environmental protection acceptance monitoring report" for the full publication as follows:
Project name: Shanxi Nuocheng Pharmaceutical Co., Ltd. to expand the annual output of 2 × 63 tons of amino acid derivatives series, annual output of 2 × 4 tons of cimetidine raw material drug product production line project (phase)
Project summary: Shanxi Nuocheng Pharmaceutical Co., Ltd. rebuilds and expands the production line of 2 × 63 tons of amino acid derivative series and 2 × 4 tons of cimetidine bulk drug products (phase). It is located in Shanxi Nuocheng Pharmaceutical Co., Ltd. in the pharmaceutical park of Huairen Economic and Technological Development Zone. Now the first workshop of bulk drug and its supporting environmental protection and public auxiliary facilities have been completed, the scope of environmental protection acceptance for this phased completion is the first workshop of bulk drug and its supporting environmental protection and public and auxiliary facilities. The construction scale is 60 tons of fluorenylmethoxycarbonyl-N-hydroxysuccinic acid imide ester (FMOC-OSU), 3 tons of N-fluorenylmethoxycarbonyl-tyrosine (tert-butyl ether)(Fmoc-Tyr(tBu)-OH) and 4 tons of cimetidine. On May 18, 2021, Shuozhou Administrative Examination and Approval Service Administration issued Shuo Approval Letter [2021] No. 59 to "Regarding the reconstruction and expansion of Shanxi Nuocheng Pharmaceutical Co., Ltd. with an annual output of 2 × 63 tons of amino acid derivative series and an annual output of 2 × 63 tons." 4 tons of cimetidine API production line project environmental impact report "was approved. The actual 31 million yuan for phased projects, including 770000 yuan for environmental protection.
Publicity time: May 24, 2023-June 20, 2023 (20 working days)
Publicity period: if you have any objection to the above publicity contents, please give feedback in written form. The individual must sign his real name and the unit must affix his official seal.
Construction unit: Shanxi Nuocheng Pharmaceutical Co., Ltd.
Contact: Li Jianjun
Telephone:13903526739
Address: Shanxi Nuocheng Pharmaceutical Co., Ltd., Medical Park, Huairen Economic and Technological Development Zone, Huairen City, Shanxi Province
[Jinshan Document] Acceptance Report of Norcheng Pharmaceutical (Phased Project). pdf
https://kdocs.cn/l/cjXLk2aMtsVs?f=201?
[Jinshan Document] Acceptance Opinions of Norcheng Pharmaceutical
https://kdocs.cn/l/cqqnFl9qr7bN
[Jinshan Document] Test Report of Norcheng Pharmaceutical (Phase Project)
Key words:
Biopharmaceuticals
2023-07-02
Self-monitoring programme in 2023
2023-06-26
Fuze the world, a promise will be made!
Norcheng Pharmaceuticals
Copyright©2023 Shanxi Nuocheng Pharmaceutical Co., Ltd.